Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Conagen

Explore full profile

Synthetic Biology And Biological Engineering Company

Bedford, United StatesFounded 2010Food
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Conagen and the history behind them.

About Conagen

Founded in 2010 by Dr. Oliver Yu, Conagen is a vertically integrated synthetic biology and biotechnology company. Dr. Yu, the company's CEO, brings extensive experience in metabolic engineering, with a background that includes a Ph.D. from the University of South Carolina, postdoctoral training at DuPont, and a tenure as a Principal Investigator at the Donald Danforth Plant Science Center. His academic and research career, which includes over 120 manuscripts and patents, is foundational to Conagen's scientific approach.

The company operates by using synthetic biology and precision fermentation to manufacture high-value ingredients for a diverse client base. Its business model focuses on providing these bio-manufactured products to companies in the food and beverage, flavor and fragrance, nutrition, pharmaceutical, and renewable materials sectors. Conagen generates revenue by serving these business-to-business markets, leveraging its vertically integrated structure that encompasses everything from initial strain development to commercial-scale production, ensuring speed to market.

Conagen's core service is the development and production of natural products through advanced biological processes. The company engineers microorganisms and utilizes fermentation to create a wide array of molecules, including natural sweeteners, flavors, fragrances, nutraceuticals, and specialty chemicals. Key technological capabilities include strain development, metabolic pathway engineering, and fermentation process development. The company has established proprietary production platforms for major molecular classes like terpenoids, phenolics, and lipids, and uses high-throughput automation and robotics to screen vast numbers of microbial strains efficiently. This bio-manufacturing approach allows for the sustainable and scalable production of ingredients that may be difficult to source through traditional agriculture or chemical synthesis. A significant milestone was a $30 million strategic investment from Sumitomo Chemical in 2020, aimed at accelerating research and developing sustainable chemicals.

Source: Dealroom company data

At a glance

Founded
2010
Headquarters
Bedford, United States
Sector
Food

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • US National Science Foundation

Series B and later1 investor entered at this stage

  • Sumitomo Chemical
Employees 20 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Conagen on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Conagen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.